October 19, 2023 Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® demonstrates no increased risk in major adverse cardiac events in a large, long-term real-world evidence study Read more
March 6, 2023 Currax Files Lawsuit Against Found Health for False Marketing of Generic Equivalent of CONTRAVE® Read more
